Fabry Disease Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Fabry Disease Market Overview

Fabry disease is a rare inherited disorder that can affect multiple organs, with manifestations involving the kidneys, heart, nervous system, and skin. Its progressive nature often requires long-term disease management, monitoring, and specialized care to address organ complications and improve patient outcomes. The market is supported by increasing disease awareness, improved diagnostic capabilities, and advances in targeted treatment approaches. The market is poised to grow at a CAGR of 7.50% during the forecast period of 2026-2035. The growing adoption of enzyme replacement and chaperone therapies, alongside emerging gene therapy programs, is expanding treatment options. Increased clinical research and efforts to enable earlier diagnosis are also supporting market development.

Fabry Disease Market Growth Analysis and Key Influencers

Fabry Disease Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Fabry Disease Market Growth Drivers

Rising Disease Prevalence and Treatment Needs to Support Market Expansion

The increasing recognition of Fabry disease and the need for lifelong disease management are supporting the demand for effective therapies. According to Sanofi, Fabry disease is an X-linked lysosomal storage disorder that affects males, females, and children across ethnicities, with an estimated prevalence of approximately 1 in 40,000 males and 1 in 20,000 females. The disease results from deficient alpha-galactosidase A activity and can cause progressive damage to the kidneys, heart, nervous system, eyes, skin, and other organs. The resulting need for continuous disease management and treatment is expected to sustain market growth.

Fabry Disease Market Restraints

Gene Therapy Safety Risks May Constrain Market Expansion

Safety concerns surrounding investigational gene therapies may limit market development by increasing clinical, regulatory, and investment risks. For instance, in February 2026, uniQure paused dosing in the medium- and high-dose cohorts of its Phase I/IIa AMT-191 trial after two of 11 enrolled patients experienced asymptomatic Grade 3 liver enzyme elevations, both classified as dose-limiting toxicities following independent review. Although the patients responded to corticosteroid treatment and AMT-191 demonstrated increased alpha-galactosidase A activity, the findings highlight safety uncertainties that could delay development and adoption of emerging gene therapies.

Fabry Disease Market Opportunities

One-Time Gene Therapies Create New Growth Potential

Advances in one-time gene therapy are creating potential for treatments that could reduce the burden associated with lifelong enzyme replacement therapy. For instance, in March 2023, Emory University reported clinical research evaluating an adeno-associated virus-based gene therapy designed to deliver genetic material encoding the deficient enzyme to the liver. The approach aims to enable sustained enzyme production and potentially overcome limitations of repeated enzyme replacement, including intermittent effects and antibody development. Continued clinical development of these approaches is expected to expand treatment options and support future market growth.

Fabry Disease Market Trends

Some of the notable trends in the market are sustained enzyme expression, gene therapy innovation, and reduced treatment burden.

Sustained Enzyme Production Is Likely to Elevate the Market Growth

The market is increasingly moving toward gene therapies designed to provide sustained alpha-galactosidase A production and reduce dependence on repeated treatments. For instance, in September 2025, uniQure reported that all four patients in the first AMT-191 cohort achieved 27- to 208-fold increases in alpha-galactosidase A activity relative to the mean normal level, with sustained increases observed for up to 45 weeks. All four patients discontinued enzyme replacement therapy while maintaining stable plasma lyso-Gb3 levels, highlighting the potential for durable treatment approaches to support market growth.

Fabry Disease Market Share

Enzyme Replacement Therapy Is Expected to Maintain Market Leadership by Treatment Type

The market is segmented by treatment type into enzyme replacement therapy (ERT), chaperone therapy, gene therapy, supportive and symptomatic therapy, and others. Among these, enzyme replacement therapy is expected to maintain a leading position because it remains an established treatment approach for long-term disease management. For instance, in March 2026, Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the European Commission approved a 2 mg/kg every four weeks dosing regimen for Elfabrio (pegunigalsidase alfa) in adults with Fabry disease who are stable on ERT. The change extends the infusion interval from every two weeks to every four weeks, potentially reducing treatment burden while supporting continued ERT use.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Fabry Disease Market Analysis by Region

The countries included in the analysis are the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to lead, supported by its advanced rare-disease treatment infrastructure, regulatory support, and active development of innovative therapies. For instance, in August 2026, PTC Therapeutics announced its selection as the winning bidder to acquire ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, for USD 111 million upfront and up to USD 100 million in contingent milestone payments. PTC expects to complete a rolling BLA submission in the fourth quarter of 2026, with a potential commercial launch in 2027. The company estimates that approximately 11,000 people live with Fabry disease in the United States.

Leading Players in the Fabry Disease Market

Fabry Disease Market Segmentation

Key Questions Answered in the Fabry Disease Market Report

• What was the Fabry disease market value in 2025?
• What is the Fabry disease market forecast outlook for 2026-2035?
• What are the major factors aiding the Fabry disease market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Fabry disease market trends?
• Which disease type is expected to dominate the market segment?
• Which treatment type is projected to lead the market segment?
• Which indication is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Which distribution channel is expected to lead the market segment?
• Who are the key players involved in the Fabry disease market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Structured interviews and consultations with rare disease specialists, geneticists, nephrologists, cardiologists, Fabry disease treatment specialists, healthcare procurement professionals, and payer representatives across the United States, EU5, Japan, and India to assess treatment patterns, unmet needs, market access, and evolving therapeutic preferences.
• Secondary Research: Analysis of peer-reviewed literature, clinical trial records, epidemiological publications, regulatory information from the US FDA, EMA, PMDA, and CDSCO, and company disclosures from leading Fabry disease market participants, including Sanofi S.A., Takeda Pharmaceutical Company Limited, GSK plc, Chiesi Farmaceutici S.p.A., and Protalix BioTherapeutics Inc.
• Validation: Market estimates are triangulated through top-down and bottom-up modeling, cross-checked against epidemiological, treatment, pricing, company, and regulatory data, and refined through expert validation.